Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT
- New next-gen SPEAR T-cells (ADP-A2M4N7X19) designed to enhance depth and durability of clinical response demonstrated enhanced proliferation, survival, and recruitment of immune cells in vitro -
- Engineered TILs (ADP-TILIL7) intended to improve clinical responses, produced levels of IL-7 shown to improve growth and survival in vitro -
- The Company is planning to initiate a Phase 1 trial with ADP-A2M4N7X19 in multiple solid tumors and a single-center, Phase 1 trial with ADP-TILIL7 for people with metastatic melanoma -
PHILADELPHIA. and OXFORD, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, is presenting preclinical proof-of-concept data from its second next-generation SPEAR T-cell (ADP-A2M4N7X19) targeting MAGE-A4, and novel tumor-infiltrating lymphocytes (TILs) expressing IL-7 (ADP-TILIL7) at the American Society of Gene & Cell Therapy (ASGCT) annual meeting. The Company is presenting the two posters today at 5:30 p.m. EDT during the Cell Therapies I and Targeted Gene and Cell Therapy I sessions.
“We have seen impressive clinical results with our first-generation product, afami-cel, in sarcoma, and we set a goal to increase potency to achieve responses in additional indications,” said Elliot Norry, Adaptimmune’s Chief Medical Officer. “To that end, we delivered our first next-gen product into the clinic incorporating CD8 and have shown responses across a broad range of solid tumor types in our SURPASS program. We have now presented preclinical data at ASGCT from our second next-gen therapy designed to improve durability and persistence of SPEAR T-cells that supports clinical investigation.”
New next-generation SPEAR T-cells show potential for enhanced clinical activity with improved proliferation, survival, and infiltration of immune cells into tumors in preclinical studies
TILs engineered to produce IL-7 may result in a more effective therapy for people with metastatic melanoma with preclinical data demonstrating enhanced TIL survival
The Company will also present a poster entitled “A Novel Flow Cytometry Method for Rapid Assessment of Lentiviral Detection” on May 19th.
Sébastien Desprez — VP, Corporate Affairs and Communications
Juli P. Miller, Ph.D. — VP, Investor Relations